August 24 2022 - 07:30AM
GlobeNewswire Inc.
Alert
Share On Facebook
SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced additional positive pre-clinical results of its Psychedelic-based Pharma Collaboration for treatment for cocaine addiction using MEAI, a novel psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0).
These pre-clinical study results add to SciSparc’s recent announcements regarding the Company's collaboration with Clearmind for their combination treatment based on SciSparc’s CannAmide™ compound and Clearmind’s MEAI for various addictions, including pre-clinical studies results, the filing of two provisional patent applications related to compositions comprising MEAI and n-acylethanolamines and uses thereof and treating cocaine addiction.
"We are excited about these recent results in light of the potential synergistic effect between SciSparc’s CannAmide and Clearmind’s MEAI, as previously demonstrated. These results continue to indicate that we may have a targeted treatment for cocaine addiction within our reach,” commented Oz Adler, SciSparc's Chief Executive Officer. "These results reinforce our decision to enter a collaboration between the two companies."
The pre-clinical trial was led by Professor Gal Yadid and his team from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel) and was designed to evaluate the possible reward-like effects of MEAI with connection to cocaine and its ability to abolish cocaine-induced conditioned place preference.
In the pre- clinical trial, the self-administration paradigm was utilized, which is the gold-standard model for examining drug addiction and is based on operant conditioning. Rats were catheterized and trained to self-administer cocaine.
The results identified a statistically significant sub-group within the study, in a non-biased manner and high integrity, which dramatically responded to the treatment, significantly decreasing the craving for cocaine as compared to non-treated control group. This sub-group, representing 60% of animals, showed a very high response within the group.
About SciSparc Ltd. (NASDAQ:SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome and for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus.
About Clearmind Inc. (CSE: CMND), (OTC: CMNDF), (FSE: CWY0)
Clearmind is a new biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disord
Recent SPRC News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 11:13:53 AM
- SciSparc Secures Strategic Advantage with Grant of European Patent • GlobeNewswire Inc. • 05/31/2024 11:17:00 AM
- SciSparc to Acquire AutoMax • GlobeNewswire Inc. • 04/11/2024 12:15:00 PM
- SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research • GlobeNewswire Inc. • 03/21/2024 12:58:00 PM
- SciSparc Granted Another Patent, Strengthening its Core Technology in Canada • GlobeNewswire Inc. • 03/18/2024 11:29:00 AM
- SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial • GlobeNewswire Inc. • 03/14/2024 12:49:00 PM
- SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure • GlobeNewswire Inc. • 03/12/2024 12:14:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/08/2024 02:00:02 PM
- SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder • GlobeNewswire Inc. • 03/08/2024 12:11:00 PM
- SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe • GlobeNewswire Inc. • 03/07/2024 12:49:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/07/2024 05:15:11 AM
- SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology • GlobeNewswire Inc. • 03/06/2024 09:41:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/29/2024 02:07:12 PM
- SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing • GlobeNewswire Inc. • 02/29/2024 01:35:00 PM
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 02/27/2024 09:15:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/27/2024 01:35:07 PM
- SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds • GlobeNewswire Inc. • 02/27/2024 12:58:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2024 09:27:17 PM
- Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds • GlobeNewswire Inc. • 02/20/2024 12:14:00 PM
- SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds • GlobeNewswire Inc. • 02/20/2024 12:14:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/12/2024 09:27:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/29/2024 09:00:11 PM
- SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder • GlobeNewswire Inc. • 01/29/2024 12:18:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/25/2024 02:05:42 PM
DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • SONGD • Jun 7, 2024 10:15 AM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM